| Q92711624 | A Case of Advanced Gastric Cancer with Peritoneal Metastasis Treated Successfully with Nivolumab |
| Q37747153 | A Century of Radiation Therapy and Adaptive Immunity |
| Q89458944 | A Phase I/II Trial of 5-Fraction Stereotactic Radiosurgery with 5-mm Margins with Concurrent Temozolomide in Newly Diagnosed Glioblastoma: Primary Outcomes |
| Q38679488 | A perspective on the impact of radiation therapy on the immune rheostat |
| Q37615827 | A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response |
| Q36651935 | A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II) |
| Q53186440 | A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma. |
| Q58773898 | Abscopal effect of radiotherapy combined with immune checkpoint inhibitors |
| Q48238878 | Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. |
| Q47899811 | Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. |
| Q38984862 | Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma |
| Q37189966 | Addressing the Symptoms or Fixing the Problem? Developing Countermeasures against Normal Tissue Radiation Injury. |
| Q38767892 | Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities |
| Q57813529 | An Anti-Tumor Immune Response is Evoked By Partial-Volume Single Dose Radiation in Two Murine Models |
| Q38139854 | Antitumor immune responses induced by ionizing irradiation and further immune stimulation |
| Q93009957 | Biologically effective dose (BED) escalation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma patients (≤5 cm) with CyberKnife: protocol of study |
| Q92908909 | Biologically effective dose (BED) of stereotactic body radiation therapy (SBRT) was an important factor of therapeutic efficacy in patients with hepatocellular carcinoma (≤5 cm) |
| Q89663687 | CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection |
| Q30235014 | Cancer immunotherapy: how low-level ionizing radiation can play a key role |
| Q27024438 | Cancer vaccines |
| Q35598951 | Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation |
| Q26742107 | Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy |
| Q101574150 | Chemoradiation impairs myofiber hypertrophic growth in a pediatric tumor model |
| Q89610924 | Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models |
| Q56891584 | Combination treatment of VLA-4 targeted radionuclide therapy and immunotherapy in a mouse model of melanoma |
| Q64928975 | Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient. |
| Q34582640 | Combinations of immunotherapy and radiation in cancer therapy. |
| Q64056694 | Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma |
| Q61448764 | Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer? |
| Q56892705 | Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer |
| Q27021428 | Combining radiotherapy and cancer immunotherapy: a paradigm shift |
| Q38679418 | Combining radiotherapy with immunotherapy: the past, the present and the future |
| Q52726703 | Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients. |
| Q34032559 | Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation |
| Q37045283 | Cytokines in radiobiological responses: a review |
| Q94474304 | DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer |
| Q34438000 | Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells |
| Q33911452 | Differential expression of stress and immune response pathway transcripts and miRNAs in normal human endothelial cells subjected to fractionated or single-dose radiation |
| Q37709102 | Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer |
| Q41475564 | Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy |
| Q38727923 | Enhancing radiotherapy for lung cancer using immunoadjuvants delivered in situ from new design radiotherapy biomaterials: a preclinical study. |
| Q87827392 | Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer |
| Q38799946 | Fractionated radiotherapy combined with PD-1 pathway blockade promotes CD8 T cell-mediated tumor clearance for the treatment of advanced malignancies |
| Q33751085 | Gene and miRNA expression profiles of mouse Lewis lung carcinoma LLC1 cells following single or fractionated dose irradiation. |
| Q64110950 | Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma |
| Q64912640 | Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. |
| Q33884923 | Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer |
| Q38174601 | Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity |
| Q37676065 | Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy |
| Q41167610 | Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. |
| Q38170122 | Immune modulation and stereotactic radiation: improving local and abscopal responses. |
| Q48193633 | Immune recognition of irradiated cancer cells |
| Q39044147 | Immuno-Oncology: The Third Paradigm in Early Drug Development |
| Q58796914 | Immunologically effective dose: a practical model for immuno-radiotherapy |
| Q96954537 | Immunomodulation of NK Cells by Ionizing Radiation |
| Q38632924 | Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection |
| Q90609334 | Immunotherapy and Radiation - A New Combined Treatment Approach for Bladder Cancer? |
| Q33645613 | Immunotherapy and radiation therapy for malignant pleural mesothelioma. |
| Q38763935 | Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? |
| Q53704789 | Immunotherapy for Head and Neck Squamous Cell Carcinoma. |
| Q38543250 | In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment |
| Q36210670 | In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer |
| Q37592814 | Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy |
| Q38771934 | Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. |
| Q90218743 | Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas |
| Q91587573 | Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach? |
| Q43110773 | Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients |
| Q97527032 | Low Lymphocyte Count Is Associated With Radiotherapy Parameters and Affects the Outcomes of Esophageal Squamous Cell Carcinoma Patients |
| Q39321633 | Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer |
| Q26744490 | Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation |
| Q37670436 | Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer |
| Q94474333 | Nanomedicines based on nanoscale metal-organic frameworks for cancer immunotherapy |
| Q90282942 | Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy |
| Q55233806 | Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. |
| Q33847819 | News Feature: Radiation redux |
| Q64075507 | Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy |
| Q57494906 | Novel biological strategies to enhance the radiation therapeutic ratio |
| Q38539957 | Opportunities and challenges of radiotherapy for treating cancer |
| Q37118895 | Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era |
| Q93020582 | Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination |
| Q52888621 | Optimizing Radiotherapy with Immunotherapeutic Approaches. |
| Q38241599 | Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review |
| Q38807704 | Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases |
| Q61805065 | Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment |
| Q52659190 | PACIFIC trial: new perspectives for immunotherapy in lung cancer. |
| Q64903999 | PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. |
| Q26765024 | PD-1/PD-L1 blockades in non-small-cell lung cancer therapy |
| Q41334725 | Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma |
| Q61797413 | Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer |
| Q34333155 | Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer |
| Q43179865 | Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy |
| Q46708524 | Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers |
| Q38681083 | Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). |
| Q60907498 | Preliminary Study of the Effect of Stereotactic Body Radiotherapy (SBRT) on the Immune System in Lung Cancer Patients Unfit for Surgery: Immunophenotyping Analysis |
| Q59808608 | Preoperative Stereotactic Radiosurgery for Brain Metastases |
| Q59808472 | Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells |
| Q35693267 | Quantitative proteomic analysis of single or fractionated radiation-induced proteins in human breast cancer MDA-MB-231 cells |
| Q44243898 | Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway |
| Q38598522 | Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy |
| Q42724344 | Radiation and immunotherapy: a synergistic combination. |
| Q92906894 | Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges |
| Q36347177 | Radiation as an immunological adjuvant: current evidence on dose and fractionation. |
| Q59800762 | Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade |
| Q47703452 | Radiation effects on antitumor immune responses: current perspectives and challenges |
| Q26865395 | Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored |
| Q47098450 | Radiation generates an abscopal response and complete resolution of metastatic squamous cell carcinoma of the anal canal: a case report |
| Q27005913 | Radiation meets immunotherapy - a perfect match in the era of combination therapy? |
| Q36083353 | Radiation takes its Toll |
| Q55491553 | Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. |
| Q37190440 | Radiation therapy generates platelet-activating factor agonists |
| Q60956725 | Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation |
| Q57161810 | Radiation, inflammation and the immune response in cancer |
| Q55294642 | Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway. |
| Q28080006 | Radiation-induced immune responses: mechanisms and therapeutic perspectives |
| Q33627023 | Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions |
| Q92952824 | Radiation-induced tumor immunity in patients with non-small cell lung cancer |
| Q47405972 | Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. |
| Q37589407 | Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen |
| Q59806702 | Radiotherapy and immune response: the systemic effects of a local treatment |
| Q27022685 | Radiotherapy and the tumor stroma: the importance of dose and fractionation |
| Q60954603 | Radiotherapy as a New Player in Immuno-Oncology |
| Q26738443 | Radiotherapy combination opportunities leveraging immunity for the next oncology practice |
| Q38981347 | Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment |
| Q50500197 | Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry. |
| Q55002491 | Recommendations for In Vitro and In Vivo Testing of Magnetic Nanoparticle Hyperthermia Combined with Radiation Therapy. |
| Q38955193 | Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation. |
| Q42115384 | Regulatory T cells in radiotherapeutic responses |
| Q50746388 | Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. |
| Q64266519 | Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment |
| Q98157769 | SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges |
| Q50044559 | Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors |
| Q89097028 | Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy |
| Q42448191 | Selected anti-tumor vaccines merit a place in multimodal tumor therapies |
| Q39208496 | Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors |
| Q38904089 | Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors |
| Q57146748 | Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma? |
| Q35328111 | Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen |
| Q38828265 | Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy? |
| Q42344264 | Stereotactic body radiotherapy in the era of radiotherapy with immunotherapy |
| Q91899217 | Synergistic effects of anti-PDL-1 with ablative radiation comparing to other regimens with same biological effect dose based on different immunogenic response |
| Q38955929 | TGF-β1 mediates the radiation response of prostate cancer |
| Q64071654 | Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy |
| Q92941721 | The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response |
| Q64967557 | The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. |
| Q54942438 | The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules. |
| Q61813053 | The Response of Prostate Cancer to Androgen Deprivation and Irradiation Due to Immune Modulation |
| Q97526987 | The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy |
| Q89892410 | The abscopal effect 67 years later: from a side story to center stage |
| Q94487070 | The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy |
| Q38054113 | The confluence of radiotherapy and immunotherapy |
| Q26995372 | The effect of radiation on the immune response to cancers |
| Q38689389 | The future of personalised radiotherapy for head and neck cancer |
| Q52720460 | The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses. |
| Q37518395 | The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications |
| Q97540710 | The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells |
| Q26783291 | The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy |
| Q90655326 | The role of radiation therapy in the treatment of metastatic cancer |
| Q47876974 | The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer. |
| Q58608193 | Time to abandon single-site irradiation for inducing abscopal effects |
| Q90521349 | Tumor Size Matters-Understanding Concomitant Tumor Immunity in the Context of Hypofractionated Radiotherapy with Immunotherapy |
| Q37666685 | Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. |
| Q27001216 | Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy |
| Q50200709 | Why is survival after pembrolizumab affected by previous radiotherapy? |
| Q89862638 | [Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer] |